Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

Recruiting now

Conditions studied: Long Term Follow-up

In brief

This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study \[EOS\] visit) from their imdusiran clinical trial (the "parent study"). No interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or NA therapy if restarted. Study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off NA therapy, inclusive of parent study participation).

Key facts

Study ID
NCT06277037
Run by
Arbutus Biopharma Corporation
People needed
50
Starts
2024-07-11
Expected to finish
2029-10-30
Last updated by the study team
2024-11-27

Who can join

Age: 20 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.